Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities
- None.
- None.
Insights
The issuance of Patent No. 11,894,123 B2 to Sensus Healthcare represents a significant enhancement to the company's intellectual property portfolio. From a medical device perspective, the integration of high-frequency ultrasound with optical imaging data in radiotherapy systems could signify a leap in precision and personalization of cancer treatments. The ability to create a 3D image that guides treatment planning may lead to more effective and less invasive procedures, potentially improving patient outcomes and reducing recovery times.
Moreover, the inclusion of workflow management features such as scheduling and equipment status monitoring could streamline clinical operations, possibly leading to increased efficiency and reduced costs. These advancements may also position Sensus Healthcare favorably in a competitive market where technological innovation is a key differentiator. However, the practical application and adoption rate of this technology in clinical settings will be crucial in determining its market impact.
From a legal standpoint, the grant of a new patent provides Sensus Healthcare with a competitive edge by safeguarding their invention from potential infringement by competitors. The coverage of 33 individual claims indicates a broad protection scope, which could deter competitive entries and imitation products. This legal protection is vital for sustaining innovation and ensuring a return on investment in research and development.
However, it is important to monitor the enforcement of this patent, as well as any potential challenges or disputes that may arise. The strength of a patent is often tested through litigation and the ability of Sensus Healthcare to defend its patent rights will be instrumental in maintaining its exclusivity in the market.
From a market perspective, the announcement of a new patent for a medical device company like Sensus Healthcare can have implications for investor sentiment and the company's market valuation. Intellectual property such as patents can be a critical asset that contributes to a company's valuation, often factored into the stock price. The SRT-100 Vision system's potential to innovate within the oncology treatment space could attract interest from investors seeking growth opportunities in the healthcare technology sector.
Long-term, the success of this patented technology will depend on its clinical adoption and the demonstration of improved patient outcomes compared to existing treatments. Should the technology prove to be superior, it could lead to increased market share and revenue growth for Sensus Healthcare. Stakeholders will be watching closely for further developments, such as partnerships, clinical trials and sales performance, that could influence the company's financial trajectory.
BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management System.”
This new patent covers systems and methods for treating a patient with a radiotherapy system combining high-frequency ultrasound and optical imaging data. This proprietary technology is essentially a treatment-planning system that is made possible by fusing together a radiation therapy device with a high-frequency ultrasound (the SRT-100 Vision). The 3D image will then guide the clinician to a treatment suggestion to create a treatment plan. It also covers scheduling patient appointments, detecting medical equipment status and communicating information on status to the communication device of a service engineer. The patent covers 33 individual claims.
“The SRT-100 Vision (IG-SRT) is increasingly important to Sensus, and this new U.S. patent adds to our valuable intellectual property portfolio comprised of both domestic and international patents,” said Michael Sardano, president and general counsel of Sensus Healthcare. “This USPTO issuance helps to ensure that our innovative products will remain protected for many years to come.”
The patent may be found on the USPTO website here.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to return to profitability; our ability to sell the number of SRT units we anticipate for the balance of 2024; the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
FAQ
What is the ticker symbol for Sensus Healthcare, Inc.?
What does the new patent issued by the USPTO cover?
Who is the president and general counsel of Sensus Healthcare?
What is the title of the new patent issued by the USPTO?
Where can the patent be found?
